



Correction: Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis

Hiroki Maruyama, MD, PhD¹, Kaori Miyata, BA², Mariko Mikame, BEd¹, Atsumi Taguchi, PhD¹, Chu Guili, MD, PhD¹, Masaru Shimura, MD³, Kei Murayama, MD, PhD³, Takeshi Inoue, MD, PhD⁴, Saori Yamamoto, MD, PhD⁵, Koichiro Sugimura, MD, PhD⁵, Koichi Tamita, MD⁶, Toshihiro Kawasaki, RDCS⁶, Jun Kajihara, MD⁷, Akifumi Onishi, MD⁸, Hitoshi Sugiyama, MD, PhD⁸, Teiko Sakai, MD⁹, Ichijiro Murata, MD, PhD¹⁰, Takamasa Oda, MD, PhD¹¹, Shigeru Toyoda, MD, PhD¹², Kenichiro Hanawa, MD, PhD¹³, Takeo Fujimura, MD, PhD¹⁴, Shigehisa Ura, MD¹⁵, Mimiko Matsumura, MD¹⁶, Hideki Takano, MD, PhD¹⁶, Satoshi Yamashita, MD¹⁷, Gaku Matsukura, MD¹⁷, Ryushi Tazawa, MD, PhD¹⁸, Tsuyoshi Shiga, MD, PhD¹⁹, Mio Ebato, MD, PhD²⁰, Hiroshi Satoh, MD, PhD²¹ and Satoshi Ishii, PhD²²

Genetics in Medicine (2019) 21:1263; https://doi.org/10.1038/s41436-019-0447-8

Correction to: Genetics in Medicine; https://doi.org/10.1038/gim.2018.31; published online 15 March 2018

The HTML version of this Article contained errors in Supplementary Figure S2 "Flowchart of the lyso-Gb3 screening and gene analysis in female patients", which have been detailed in the associated Correction.

```
The upper square
```

Female with clinical symptoms suggestive of Fabry disease; "(n = 1036)" was revised to "(n = 1035)." Neurology; "(n = 227)" was revised to "(n = 226)."

The second square from the top (left side) Positive lyso-Gb3 screen; "(n = 15)" was revised to "(n = 14)." Neurology; "(n = 2)" was revised to "(n = 1)."

The third square from the top (second square from the left) Normal α -Gal A; "(n=8)" was revised to "(n=7)." Neurology; "(n=1)" was revised to "(n=0)."

The fourth square from the top (second square from the left) "Neurology (n = 1)" was deleted.

The revised Supplementary Information can be found as Supplementary Information associated with this Correction.

SUPPLEMENTARY INFORMATION

The online version of this article (https://doi.org/10.1038/s41436-019-0447-8) contains supplementary material, which is available to authorized users.

Published online: 6 February 2019

¹Department of Clinical Nephroscience, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan; ²Sanofi K.K., Sanofi Genzyme Medical Operations, Rare Disease Medical, Medical Science Liaison, Tokyo, Japan; ³Department of Metabolism, Chiba Children's Hospital, Chiba, Japan; ⁴Department of Pediatrics, Dokkyo Medical University Koshigaya Hospital, Koshigaya, Japan; ⁵Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan; ⁸Nishinomiya Watanabe Cardiovascular Center, Nishinomiya, Japan; ⁷Department of Cardiology, Fujinomiya City General Hospital, Fujinomiya, Japan; ⁸Department of Human Resource Development of Dialysis Therapy for Kidney Disease, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan; ⁹Sukoyaka Clinic, Gifu, Japan; ¹⁰Department of Chronic Kidney Disease, Gifu University Graduate School of Medicine, Gifu, Japan; ¹¹Yamaguchi Prefectural Grand Medical Center, Hofu, Japan; ¹²Department of Cardiovascular Medicine, Dokkyo Medical University, Mibu, Japan; ¹³Department of Cardiology, Internal Medicine, Iwaki Kyoritsu General Hospital, Iwaki, Japan; ¹⁴Department of Nephrology, Kashiwazaki General Hospital and Medical Center, Kashiwazaki, Japan; ¹⁵Division of Neurology, Japanese Red Cross Asahikawa Hospital, Asahikawa, Japan; ¹⁶Department of Nephrology, Tokyo Teishin Hospital, Tokyo, Japan; ¹⁷Department of Cardiology, Japan; ¹⁸Division of Medical Genetics, Bioscience Medical Research Center, Niigata University Medical and Dental Hospital, Niigata, Japan; ¹⁹Department of Cardiology, Tokyo Women's Medical University, Tokyo, Japan; ²⁰Division of Cardiology, Showa University Fujigaoka Hospital, Yokohama, Japan; ²¹Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu, Japan; ²²Glyco Pharma Corporation, Oita, Japan. Correspondence: Hiroki Maruyama (hirokim@med.niigata-u.ac.jp)